Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex F Herrera

Showing results (31-40 of 175) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|October 10, 2025
Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphomaNicolás Triantafilo, Arnab Chowdhury, Swetha Thiruvengadam, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2022
PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin LymphomaSwetha Kambhampati Thiruvengadam, Matthew G Mei, James Godfrey, et al.
Blood Advances|July 16, 2025
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, John M Timmerman, et al.
Blood Advances|January 27, 2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNAAlex F Herrera, Samuel Tracy, Brandon Croft, et al.
Transplantation and Cellular Therapy|March 5, 2025
Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab TherapyJohn Kuruvilla, Philippe Armand, Alex F Herrera, et al.
American Journal of Hematology|October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAlex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Hemasphere|August 11, 2025
Working towards harmonization of clinical trial reporting in Hodgkin lymphomaCarsten Kobe, Philippe Armand, Sven Borchmann, et al.
Leukemia & Lymphoma|October 31, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphomaPaolo Lopedote, Geoffrey Shouse, Lu Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin LymphomaMatthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.
Transplantation and Cellular Therapy|July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular TherapyAbraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Pageof 18

Showing results (31-40 of 175) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|October 10, 2025
Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphomaNicolás Triantafilo, Arnab Chowdhury, Swetha Thiruvengadam, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2022
PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin LymphomaSwetha Kambhampati Thiruvengadam, Matthew G Mei, James Godfrey, et al.
Blood Advances|July 16, 2025
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, John M Timmerman, et al.
Blood Advances|January 27, 2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNAAlex F Herrera, Samuel Tracy, Brandon Croft, et al.
Transplantation and Cellular Therapy|March 5, 2025
Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab TherapyJohn Kuruvilla, Philippe Armand, Alex F Herrera, et al.
American Journal of Hematology|October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAlex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Hemasphere|August 11, 2025
Working towards harmonization of clinical trial reporting in Hodgkin lymphomaCarsten Kobe, Philippe Armand, Sven Borchmann, et al.
Leukemia & Lymphoma|October 31, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphomaPaolo Lopedote, Geoffrey Shouse, Lu Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin LymphomaMatthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.
Transplantation and Cellular Therapy|July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular TherapyAbraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Pageof 18